Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven

Gerhardt Attard, Alison H M Reid, Timothy A Yap, Florence Raynaud, Mitch Dowsett, Sarah Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S Cooper, Stan B Kaye, David Dearnaley, Gloria Lee, Johann S de Bono

Research output: Contribution to journalArticlepeer-review

802 Citations (Scopus)


Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.
Original languageEnglish
Pages (from-to)4563-71
Number of pages9
JournalJournal of Clinical Oncology
Issue number28
Publication statusPublished - 1 Oct 2008


  • Adenocarcinoma
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Androstenols
  • Castration
  • Disease Progression
  • Humans
  • Male
  • Middle Aged
  • Neoplasms, Hormone-Dependent
  • Prospective Studies
  • Prostatic Neoplasms
  • Treatment Outcome

Cite this